Pure Global
NCT06297408

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus

Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Single Arm Phase I and Phase II Randomized Controlled Open, Multicenter Study
Shanghai Ming Ju Biotechnology Co., Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
Relma-cel
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Ming Ju Biotechnology Co., Ltd.
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
May 01, 2026
Enrollment
24 participants
Primary outcome

DLT rate,determine RP2D

Summary

To assess the safety tolerability pharmacokinetics and pharmacodynamics of Relma-cel in
 moderate or severe active systemic lupus erythematosus (SLE) subjects in China.

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06297408
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06297408 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Ming Ju Biotechnology Co., Ltd. and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.